REPLY

Sir,
Kindly refer to the comments of Duggal and Nizamie on our paper. We are grateful to them for the interest shown in our paper. Our responses to their comments are given below-I. The commetators have suggested that the PANSS should have been administered before and after the wash-out period. This has been clearly stated in the methodology section that THE EDITOR PANSS was done before and after wash-out and people showing 20% improvement were dropped.
2. The concept of primary and secondary negative symptoms is still evolving and at the time the study was undertaken in 1996 this issue has not yet crystalised. That is why no attempt was made to differentiate primary from secondary negative symptoms.
3. This study was done on patient consulting the clinic, on specified days and fulfilling the inclusion and exclusion criteria. Stability of symptomatology was not a criteria. However, chronic schizophrenic patients who had acute exacerbation were excluded. It has been also clearly stated in methodology thus the patients were more or less stable.
4. There were 71 patients on 8 mg & 28 (37%) of them developed EPS whereas, 75 patients were on 6 mg & 37 (49%) developed EPS. Thus the dose of 6 and 8 mg did not show much difference on development of EPS in these patients. US/Canada study, also showed that patients on risperidone need same amount of anticholenergics as patients on haloperidol.
5. Dose escalation was done as per recommended protocol at that time. It is possible that increase in autonomic instability was due to this reason.
6. Clinical drug trial do recommend flexible dose design. In this study fixed dose design was used to study the acceptability of two recommended dosage. Earlier studies on risperidone have also used fixed dose design.
The conclusions of any study have to be interpreted keeping in mind the strength and weaknesses of the study. A good study should allow readers to make independent conclusions. Psychiatry, 1999, 41,1, 81-82) . Acute dystonia is reported to have occured in early part of therapy with commonly used psychopharmacological agents (Kuruvilla & Kuruvilla, 1995) but no case of akathisia was observed in a multicenter trial of risperidone in Indian patients with schizophrenia (Agarwal et al.,1998) . Occurence of EPS in patients receiving risperidone is said to be dose related and it has a reduced propensity to cause akathisia (Owens, 1996) . Therefore the author's observation of acute dystonia and akathisia deserves attention and a careful observation for EPS in patients receiving risperidone, is required.
REPLY
Sir,
I am grateful to Dr.S.K.Pandey for his interest and valuable comment on the article "Risperidone induced dystonia and akathisia". Though risperidone is reported to have a broad spectrum of antipsychotic activitity it has a differential side effect profile at different doses. At a dose of 6 mg per day, risperidone demonstrates higher 5-HT 2 (80-100%) than D 2 (74-83%) occupancy bordering on the extrapyramidal
THE EDITOR
threshold. At this dose the presence of potent 5-HT 2 antagonism may reduce risperidone's risk of E.P.S. in comparison with conventional antipsychotics. As the dose of risperidone is increased beyond 6 mg/day suprathreshold D 2 blockade may result and the balanced serotonin dopamine interaction may no longer be able to alleviate extrapyramidal symptoms (Kapur & Remington, 1996) . Marder et al. (1994) in a study of assessment of the efficacy of risperidone in the treatment of schizophrenia did not find any significant difference in extrapyramidal symptom rating scale score between patients who received placebo and < 6 mg of risperidone. However, in the index case report Mr.B was receiving only 6 mg of risperidone per day still he experienced dystonic reaction and intractable akathesia which was not relieved by propranolol 120 mg/day. One possible reason for the expression of these side effects at a "safer therapeutic window" could be due to racial changes in the pharmacokinetics and pharmacodynamic profile of patients in India making them more susceptible to extrapyramidal side effects. May be our patients achieving higher D 2 occupancy at a lower therapeutic dose. In contradiction to Dr.S K.Pandey's comment, 14 (8.5%) cases of akathisia has been reported in the multicenter trial of risperidone in Indian patients with schizophrenia at the end of 6 weeks therapy (Agarwal etal., 1998) . In the same series 8 (10.9%) patients had rigidity, 29 (17.6%) had hypokinesia and 37 (22.4%) had tremor at the end of trial. Out of 146 patients 75 received only 6 mg risperidone per day. A separate analysis of this two group of patients might have given more information about the relationship between risperidone's dose and extrapyramidal side effects.
A single case report can only serve to stimulate interest in further study. Future studies concurrently assessing plasma level, receptor occupancy and side effects can answer this therapeutic problem.
